Senior Scientist, Antibody Screening

Engitix Therapeutics is a pioneering biotech company dedicated to unlocking extracellular matrix biology to develop transformative therapeutics in fibrosis and oncology. We are seeking an accomplished Senior Scientist of Antibody Screening to play a lead role in selecting and characterising therapeutic antibody drug candidates.

We are looking for a highly experienced antibody screening scientist, where you will utilise your expertise to establish screening cascades for characterising the antibody hits in drug discovery programs. As a key component of this, demonstrable experience of binding assays in multiple formats and in SPR is essential. Further expertise in cell-based assays, epitope binning and/or developability profiling would be desirable.

Key responsibilities:

• Establish hit-to-lead screening cascade assays to identify potent, functional and developable monoclonal antibodies, driving project progression through key milestones
• Perform lab-based binding assays, including ELISA and SPR
• Manage CROs for antibody production and/or other antibody-related activities
• Analyse, interpret, report and present results in project meetings

• PhD in Biomedical Sciences, Immunology, Biochemistry, Biotechnology, or a related discipline, plus 3 years’ experience in a drug screening environment; or an MSc plus 6 years of practical experience with a focus on immuno-oncology or fibrosis
• Familiarity with antibody drug development is essential. As is, prior working experience in the biotech/pharma industry
• An ability to work under pressure in a fast-paced, biotech environment
• Ability to plan, execute, and critically assess experiments independently
• Excellent time-management skills and ability to work to set deadlines
• Excellent written and verbal communication skills and the ability to work effectively within a team
• Strong troubleshooting skills, with a methodical approach, high attention to detail, and the ability to maintain accurate records

• Fc effector function cell-based assays for ADCP, ADCC and CDC
• Experience of primary cell culture for cells types relevant to fibrosis and oncology research
• High-throughput screening approaches (e.g. 384-well format)
• Epitope binning and/or antigen-antibody characterisation approaches
• Antibody developability profiling